Q1 EPS Forecast for Pelthos Therapeutics Reduced by Analyst

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Research analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Pelthos Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now expects that the company will earn ($4.49) per share for the quarter, down from their previous estimate of ($1.88). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q2 2026 earnings at ($3.48) EPS, Q3 2026 earnings at ($2.29) EPS, Q4 2026 earnings at ($2.60) EPS, FY2026 earnings at ($14.39) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at $10.86 EPS, FY2029 earnings at $15.42 EPS and FY2030 earnings at $18.79 EPS.

Other equities research analysts also recently issued research reports about the company. Oppenheimer boosted their target price on Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday. Piper Sandler started coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They issued an “overweight” rating and a $48.00 price objective for the company. Zacks Research cut Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, January 30th. Finally, Roth Mkm cut their target price on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $56.25.

Pelthos Therapeutics Stock Performance

Shares of PTHS opened at $20.74 on Monday. The company has a fifty day moving average price of $23.28. The company has a market cap of $69.69 million, a price-to-earnings ratio of -1.00 and a beta of 3.86. Pelthos Therapeutics has a 52 week low of $9.00 and a 52 week high of $54.29. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15.

Hedge Funds Weigh In On Pelthos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PTHS. Boothbay Fund Management LLC increased its position in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after buying an additional 59,435 shares in the last quarter. Ikarian Capital LLC lifted its holdings in Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after acquiring an additional 193,307 shares in the last quarter. J. Goldman & Co LP bought a new position in Pelthos Therapeutics during the fourth quarter worth about $2,418,000. Cantor Fitzgerald L. P. acquired a new position in Pelthos Therapeutics in the fourth quarter valued at about $1,085,000. Finally, Diadema Partners LP increased its holdings in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares in the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

More Pelthos Therapeutics News

Here are the key news stories impacting Pelthos Therapeutics this week:

• Positive Sentiment: HC Wainwright raised long‑range earnings power — materially higher EPS forecasts for FY2028–FY2030 (FY2028 to $10.86, FY2029 to $15.42, FY2030 to $18.79) imply strong upside potential if the company executes on its development plan. This is the key reason the firm retained a Buy rating and $60 target.
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and $60 price target despite the near‑term cuts, signaling the firm still views Pelthos as a multi‑year growth/return story rather than a cut‑and‑run situation. Article Title
• Negative Sentiment: Significant downward revisions to 2026 guidance: HC Wainwright lowered Q1–Q4 2026 EPS (Q1 to ($4.49), Q2 to ($3.48), Q3 to ($2.29), Q4 to ($2.60)) and cut FY2026 from ($6.31) to ($14.39). Those large near‑term cuts increase uncertainty around upcoming cash burn, milestones and financing needs and are the most immediate negative catalyst driving today’s sell‑off. Article Title

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).